Citadel Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

Citadel Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$542K	Sell	56,885 -24,715	-30%	-$192K	﹤0.01%	9101
2025 Q4	$636K	Buy	81,600 +52,700	+182%	+$381K	﹤0.01%	8434
2025 Q3	$219K	Sell	28,900 -16,000	-36%	-$133K	﹤0.01%	11071
2025 Q2	$402K	Sell	44,900 -6,100	-12%	-$56.8K	﹤0.01%	9131
2025 Q1	$383K	Sell	51,000 -74,200	-59%	-$598K	﹤0.01%	9056
2024 Q4	$942K	Sell	125,200 -14,600	-10%	-$111K	﹤0.01%	7144
2024 Q3	$1.06M	Buy	139,800 +44,400	+47%	+$338K	﹤0.01%	6756
2024 Q2	$590K	Buy	95,400 +40,400	+73%	+$223K	﹤0.01%	7714
2024 Q1	$279K	Sell	55,000 -413,300	-88%	-$2.32M	﹤0.01%	9603
2023 Q4	$2.81M	Sell	468,300 -79,000	-14%	-$458K	﹤0.01%	4771
2023 Q3	$3.87M	Sell	547,300 -55,800	-9%	-$401K	﹤0.01%	4059
2023 Q2	$4.25M	Buy	603,100 +14,000	+2%	+$112K	﹤0.01%	3905
2023 Q1	$4.91M	Sell	589,100 -80,000	-12%	-$770K	﹤0.01%	3847
2022 Q4	$7.68M	Buy	669,100 +84,200	+14%	+$1.05M	﹤0.01%	3182
2022 Q3	$7.37M	Buy	584,900 +210,000	+56%	+$2.7M	﹤0.01%	3222
2022 Q2	$3.97M	Sell	374,900 -145,800	-28%	-$1.5M	﹤0.01%	4227
2022 Q1	$8.47M	Sell	520,700 -299,200	-36%	-$4.8M	﹤0.01%	3235
2021 Q4	$11.4M	Buy	819,900 +54,200	+7%	+$717K	﹤0.01%	2858
2021 Q3	$11M	Buy	765,700 +165,300	+28%	+$2.61M	﹤0.01%	2921
2021 Q2	$9.49M	Buy	600,400 +111,600	+23%	+$1.52M	﹤0.01%	3165
2021 Q1	$4.97M	Buy	488,800 +324,000	+197%	+$3.34M	﹤0.01%	4273
2020 Q4	$1.23M	Sell	164,800 -5,100	-3%	-$26.3K	﹤0.01%	6354
2020 Q3	$584K	Sell	169,900 -56,700	-25%	-$243K	﹤0.01%	7009
2020 Q2	$1.08M	Buy	226,600 +193,300	+580%	+$772K	﹤0.01%	5699
2020 Q1	$67K	Buy	+33,300	New	+$91.7K	﹤0.01%	8883
2019 Q4	–	Sell	-11,700	Closed	-$34K	–	9106
2019 Q3	$34K	Sell	11,700 -25,000	-68%	-$77.8K	﹤0.01%	8809
2019 Q2	$139K	Buy	36,700 +15,900	+76%	+$95.7K	﹤0.01%	8392
2019 Q1	$169K	Buy	+20,800	New	+$178K	﹤0.01%	8315
2018 Q1	–	Sell	-22,500	Closed	-$110K	–	8263
2017 Q4	$110K	Buy	22,500 +8,700	+63%	+$42.1K	﹤0.01%	7393
2017 Q3	$72K	Sell	13,800 -8,800	-39%	-$45.1K	﹤0.01%	7112
2017 Q2	$126K	Sell	22,600 -25,700	-53%	-$157K	﹤0.01%	6824
2017 Q1	$406K	Buy	48,300 +17,900	+59%	+$125K	﹤0.01%	5380
2016 Q4	$192K	Buy	30,400 +700	+2%	+$3.64K	﹤0.01%	6333
2016 Q3	$131K	Buy	29,700 +14,200	+92%	+$56.7K	﹤0.01%	6540
2016 Q2	$44K	Sell	15,500 -4,200	-21%	-$13K	﹤0.01%	6437
2016 Q1	$56K	Buy	19,700 +4,400	+29%	+$19.5K	﹤0.01%	6219
2015 Q4	$158K	Sell	15,300 -798,500	-98%	-$7.94M	﹤0.01%	6132
2015 Q3	$9.28M	Buy	813,800 +786,200	+2,849%	+$10.5M	0.01%	1401
2015 Q2	$412K	Buy	27,600 +17,800	+182%	+$202K	﹤0.01%	5272
2015 Q1	$88K	Sell	9,800 -17,900	-65%	-$185K	﹤0.01%	6937
2014 Q4	$337K	Sell	27,700 -4,700	-15%	-$51.9K	﹤0.01%	5259
2014 Q3	$317K	Sell	32,400 -40,200	-55%	-$493K	﹤0.01%	5199
2014 Q2	$926K	Hold	72,600	–	–	﹤0.01%	3600
2014 Q1	$768K	Buy	72,600 +24,200	+50%	+$258K	﹤0.01%	3763
2013 Q4	$368K	Sell	48,400 -4,900	-9%	-$31K	﹤0.01%	4387
2013 Q3	$388K	Buy	53,300 +45,000	+542%	+$228K	﹤0.01%	4077
2013 Q2	$13K	Buy	+8,300	New	+$14.3K	﹤0.01%	6170

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Citadel Advisors's BCRX Position: Q1 2026 in Review

Citadel Advisors reduced its BioCryst Pharmaceuticals (BCRX) stake by 22% in Q1 2026, selling an estimated $2.18M and leaving 1,018,743 shares worth $9.7M. The position accounts for ﹤0.01% of the portfolio, ranked #3305.

Citadel Advisors first reported a position in BCRX in Q2 2013 and has held it in 45 quarters since. The position peaked at $48.4M in Q4 2020. 301 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

Citadel Advisors held 1,018,743 shares of BioCryst Pharmaceuticals worth $9.7M as of Q1 2026.
Citadel Advisors sold 280,159 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $2.18M.
BioCryst Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #3305 holding.
Citadel Advisors first reported a position in BioCryst Pharmaceuticals in Q2 2013 and has held it in 45 quarters since.
Citadel Advisors's BioCryst Pharmaceuticals position peaked at $48.4M in Q4 2020.
301 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.